Treat-To-Target: Emergence of Second-Generation CD40L Inhibitors for Treatment of SLE-Identifying Beneficial Patient Candidates for CD40L Inhibitors in a Cross-Sectional SLE Cohort
{{output}}
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterised by heterogeneous clinical manifestations and varying degrees of organ involvement. The CD40-CD40 Ligand (CD40L) pathway is implicated in autoimmune responses, with elevated levels... ...
